Press Releases
Launch of a mutant RNA T7 polymerase with highly reduced double-stranded RNA formation
Saint-Germain-en-Laye, France – May 15, 2024 – Life Science Newswire – Takara Bio announces the launch of PrimeCap™ T7 RNA Polymerase (low dsRNA), a mutant T7 RNA polymerase suitable for mRNA therapeutic research and development.
PrimeCap T7 RNA Polymerase is a mutant T7 RNA polymerase that has been genetically engineered to maintain high-performance RNA synthesis activity while reducing dsRNA production to less than 10%. Further genetic modifications have resulted in a 4-fold reduction of cap analog concentration in the IVT reaction whilst maintaining a capping efficiency above 95%.
“There are currently two main challenges that need to be overcome in the process of in vitro mRNA synthesis: Firstly, the generation of highly immunogenic double stranded RNA during mRNA synthesis constitutes a major safety concern and, unless it can be reduced, represents a barrier to the use of mRNA therapies. Secondly, for in vitro transcribed mRNA to be translated into functional proteins, it must possess a cap structure at the 5’-end. While the use of synthetic cap analogs has proven to be a safe and effective way of adding this cap structure to synthetic mRNAs, their addition can represent up to 80% of the total cost of raw materials in the IVT reaction. We are thrilled to launch this enzyme which will remove both the technical and financial barriers to the successful production of mRNA therapeutics.” commented Dr Tarik Hadi, Senior Market Strategy Manager for mRNA Therapeutics at Takara Bio Europe.
PrimeCap T7 RNA Polymerase is currently available in research grade, however, as we continue to expand our range of GMP-grade enzymes for mRNA synthesis, we plan to release a GMP version of the enzyme shortly. This new solution is fully integrated within our comprehensive portfolio of enzymes and reagents for in vitro mRNA Synthesis; for more information, click here.
About Takara Bio Europe
Takara Bio Europe is a leading manufacturer and supplier of molecular and cellular research reagents and services. With over 25 years of experience, our high-quality, innovative tools help to accelerate translational and clinical discoveries.
Key products include SMART cDNA synthesis kits for a variety of samples and applications, including NGS, high-performance qPCR and PCR reagents (including the Takara Ex Taq®, Takara LA Taq®, Titanium®, and Advantage® enzymes), Cellartis stem cells and stem cell reagents, RT enzymes and SMART library construction kits, the innovative In-Fusion® cloning system, Guide-it gene editing tools, Tet-based inducible gene expression systems, and Living Colors® fluorescent proteins.
Takara Bio’s portfolio supports applications including NGS, gene discovery, regulation, and function studies, as well as genetic analysis, protein expression and purification, gene editing, stem cell studies, and plant and food research. For more information, visit www.takarabio.com.
Takara Bio Inc.
Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. For more information, please click here.
